Lipoprotein(a) Explained: An Inherited Heart-Risk Test

FITCNT Team July 29, 2026 7 min read
Lipoprotein(a) Explained: An Inherited Heart-Risk Test

Short answer: lipoprotein(a), written Lp(a), is an LDL-like particle and a largely inherited cardiovascular risk factor. A standard lipid panel does not report it. Because the level is mostly determined by genetics and usually remains relatively stable, many current international guidelines support measuring it at least once in adulthood.

High Lp(a) does not mean a heart attack is inevitable, and a low result does not prove low overall risk. The result should refine a broader assessment that includes LDL-C, ApoB, blood pressure, smoking, diabetes, kidney health and family history.

Key takeaway: Lp(a) is mainly a risk-identification test, not a marker athletes need to chase after every training block or PED exposure.

Table of contents

What is lipoprotein(a)?

Lp(a) contains an LDL-like ApoB particle attached to a second protein called apolipoprotein(a). The structure allows it to carry cholesterol and oxidised phospholipids and may contribute to both atherosclerosis and calcific aortic valve disease.

Every Lp(a) particle also contributes to the ApoB count. However, an ApoB test does not reveal how much of the total particle burden comes specifically from Lp(a). That requires a separate Lp(a) assay.

Why does Lp(a) matter?

Epidemiological, genetic and mechanistic evidence supports elevated Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease. Higher levels are also associated with calcific aortic valve stenosis.

Risk rises continuously with concentration rather than switching on at one perfect threshold. The clinical impact depends on the level and the person's other risk factors. Someone with high Lp(a), high ApoB, smoking and hypertension has a different total risk from someone whose modifiable factors are well controlled.

How genetic is it?

Lp(a) concentration is largely determined by variants in the LPA gene, including differences in the size of apolipoprotein(a). Lifestyle usually has a much smaller effect on the concentration than it has on LDL-C or triglycerides.

The level is often relatively stable after childhood. That is why a once-in-adulthood measurement can identify inherited risk. Repeat testing may still be appropriate when:

  • the first result is close to a decision threshold;
  • the assay or units are uncertain;
  • kidney disease, major inflammation or another condition may have affected the result;
  • a specific treatment affecting Lp(a) is used; or
  • a specialist recommends follow-up.

Who should consider testing?

Contemporary European, North American and Canadian guidance supports at least one adult measurement. It is especially relevant with:

  • premature heart attack, stroke or atherosclerotic disease;
  • a family history of premature cardiovascular disease;
  • familial hypercholesterolaemia or very high LDL-C;
  • recurrent cardiovascular events despite apparently controlled LDL-C;
  • calcific aortic valve disease; or
  • an unexplained risk pattern that the standard panel does not resolve.

Australian access and billing can vary. A GP or specialist can decide whether the test is clinically appropriate and how it fits local practice.

Units and thresholds

Laboratories report Lp(a) as either a particle concentration in nmol/L or a mass concentration in mg/dL. These are not reliably interchangeable with one universal conversion because apolipoprotein(a) particle size varies between people.

Use the unit on the report. Do not multiply by a social-media conversion factor and assume precision. Guidelines may describe risk ranges using one unit or the other, so the clinician should use the framework that matches the assay.

Why it is not on a standard lipid panel

A standard panel measures total cholesterol, LDL-C, HDL-C, triglycerides and non-HDL-C. Lp(a) requires a separate assay. Part of the cholesterol carried in Lp(a) can be included within measured or calculated LDL-C, but LDL-C cannot tell you the Lp(a) concentration.

Read the lipid-panel guide for enhanced athletes for report interpretation, and ApoB explained for athletes for particle-number context.

What athletes should know

High fitness, low body fat and a healthy diet do not guarantee low Lp(a). The level is mostly inherited. This can explain part of the risk in a family where premature cardiovascular disease occurs despite apparently healthy lifestyles.

A high result is not a reason to abandon exercise. Regular physical activity supports blood pressure, insulin sensitivity, fitness and overall risk even when it does not substantially lower Lp(a). Focus on what is modifiable.

AAS, PEDs and Lp(a)

Lp(a) is not a reliable "on-cycle" monitoring marker because genetics is the main determinant. Some hormonal and drug exposures may change it, but a lower number during one exposure would not prove lower overall risk or safety.

AAS can worsen LDL-C, ApoB, HDL-C, blood pressure, haematocrit and heart structure independently of Lp(a). Someone with inherited high Lp(a) may have an additional reason to avoid adding modifiable cardiovascular risk.

The complete heart-health guide for enhanced athletes covers the wider monitoring framework.

What happens if Lp(a) is high?

The immediate response is usually to assess and manage total risk more intensively, not to search for an unproven Lp(a) supplement. Discuss:

  • LDL-C, non-HDL-C and ApoB targets;
  • blood pressure;
  • smoking and nicotine;
  • diabetes and kidney health;
  • family screening where appropriate;
  • diet, exercise, sleep and body mass;
  • AAS and PED exposure; and
  • whether specialist assessment or imaging is clinically useful.

Lifestyle changes may not lower the Lp(a) number much, but they can lower overall cardiovascular risk. This distinction is important: a marker can be genetic while risk remains partly modifiable.

Current treatment limits

As of July 2026, no therapy is broadly approved solely to lower Lp(a). PCSK9-targeting medicines can produce modest Lp(a) reductions while substantially lowering LDL-C, and lipoprotein apheresis is used in rare, specialist situations. Treatment decisions are based on the whole clinical picture.

Several RNA-targeting medicines and an oral small molecule are in advanced trials. Large outcome studies are intended to answer whether specifically lowering Lp(a) reduces cardiovascular events. Large biomarker reductions alone are not enough to assume clinical benefit before those results and regulatory decisions.

Niacin can lower Lp(a), but adverse effects and lack of demonstrated event benefit in modern treatment settings mean it should not be self-prescribed for this purpose. Ordinary supplements have not been shown to neutralise inherited Lp(a) risk.

Frequently asked questions

What is lipoprotein(a)?

Lp(a) is an LDL-like ApoB particle attached to apolipoprotein(a). High concentrations are an inherited cardiovascular and aortic-valve risk factor.

Is Lp(a) included in a cholesterol test?

No. It requires a separate assay. A standard lipid panel cannot determine the Lp(a) concentration.

Should everyone test Lp(a)?

Many current international guidelines support at least one adult measurement, especially with premature cardiovascular disease or strong family history.

Do I need to fast for Lp(a)?

Lp(a) itself usually does not require fasting, but accompanying lipid or glucose tests may. Follow the pathology instructions.

Can I convert nmol/L to mg/dL?

There is no universally accurate conversion because particle size varies. Use the units reported by the laboratory.

Can diet lower Lp(a)?

Diet usually has little effect on the concentration, but a heart-healthy diet can still reduce overall cardiovascular risk.

Can exercise lower Lp(a)?

Exercise generally has limited effect on Lp(a) concentration but improves many other important risk factors.

Do steroids raise Lp(a)?

AAS are not best monitored with Lp(a), which is mainly genetic. They can worsen many other cardiovascular markers regardless of the Lp(a) result.

Is there a supplement for high Lp(a)?

No ordinary supplement has been shown to neutralise Lp(a)-related cardiovascular risk. Manage all modifiable factors with a clinician.

References and further reading

This article provides general education and does not interpret an individual Lp(a) result. Discuss testing and risk management with a qualified health professional.

Share:

← Back to News